A psychedelics company’s new meditation device that could save the planet
Red Light Holland Files New Patent: Technology and Devices for Monitoring Information and Influencing Behavior Involving Carbon Dioxide Emissions
Red Light Holland (TRIP) filed a patent for a new (very strange) device that might inspire the psychedelic community to be more eco-friendly.
The devices, called Wisdom Truffles, are smart lights that provide real-time data on CO2 emissions from local electricity grids, plus suggestions for reducing emissions. Oh, and they can help you meditate too.
Three models are currently under development, including a handheld meditation aid that can track physiological changes while meditating or microdosing, as well as a life-sized figurine that uses AI to create interactive experiences based on dances and stretches. Don’t worry, we’re just as confused as you… Check out the devices here.
Can shrooms help with weight loss?
Expert: Psilocybin Treatment May Support Patients With Obesity Who Have Tried Everything, Need Further Support
Experts think magic mushrooms could be the key to creating healthier habits.
In pre-clinical trials, both low and high doses of psilocybin caused rats to gain less weight when given unlimited access to food. A consultant to NeonMind Inc. (NEON) stated that psilocybin can cause a decrease in hunger by targeting 5-HT2C receptors and can give patients a sense of well-being. He explains that using psilocybin to enhance psychotherapy may be able to instill long lasting behaviour changes such as improved diet and increased exercise.
This week, NeonMind completed an integrated drug development plan for NEO-001, its high dose psilocybin treatment for weight management, which is expected to be researched in a Phase 1/2 proof-of-concept study in early 2022.
Mindset Pharma Announces Appointment of Clinician Scientist, Dr. Ishrat Husain, to Scientific Advisory Board
A new psychedelics fund launches in the US
Leading U.S.-Based Psychedelic Healthcare VC Fund Launches with $35 Million Raised to Tackle the Growing Global Mental Health Crisis
Another $35 million was just invested into US psychedelics companies.
Palo Santo, a US venture capital investment fund, invested $35 million into psychedelic research, exceeding its $30 million goal. The portfolio consists of 20 early-stage psychedelic companies with high growth potential including Atai Life Sciences, Reset Pharma, Field Trip Health, Tactogen, Eleusis, Bexson Biomedical, and more. Palo Santo’s team of investors will actively support each company in the portfolio by connecting founders, advisers, and industry leaders through their vast network in the healthcare space.
A game changer for psychedelic research in Canada
Knowde Group Inc.™ Enters Into a Strategic Partnership with LMC Manna Research to Drive Quality and Collaboration in the Conduct of Cannabis and Psychedelic Clinical Trials.
A new partnership may accelerate psychedelic research across the country to tackle the mental health crisis.
A psychedelic research organization, Knowde Group Inc., entered into a strategic partnership with Canada’s largest network of outpatient clinical research sites, LMC Manna Research. LMC Manna has 23 research sites across 3 provinces and has participated in 2,000+ clinical trials over 25 years. The collaboration will give Knowde Group access to a diverse database of over 1 million patients and strategic advisory for conducting Phase 1-4 clinical trials in psychedelic and cannabis medicines.
Red Light Holland Expected Merger Partner Creso Pharma Completes Acquisition of Halucenex Life Sciences Inc
Psilera Bioscience, a Florida startup treating illness with magic mushrooms, receives $2.5 million
A new approach to legalization in California
California Activists File Psilocybin Legalization Ballot Measure As Legislature Advances Broader Psychedelics Bill
An activist group called Decriminalize California is working to speed up the legalization of magic mushrooms.
The group submitted a new initiative called the California Psilocybin Initiative, which would legalize the possession, cultivation, retail sale, and social sharing of psilocybin mushrooms for adults 21 and over. If the Office of the Attorney General accepts the measure, the group would have 180 days to collect 623,212 signatures from registered voters for the initiative to be added to the 2022 ballot. While California’s SB519 bill would decriminalize several psychedelic drugs, this initiative takes a new approach by focusing solely on psilocybin.
Driving innovation with a new IP tool
The Complicated Patenting of Our Psychedelic Future
This new project will bring psychedelic drugs to market much faster.
A new portal for patent reviewers called Porta Sophia aims to prevent psychedelic companies from filing overly broad and invalid patents. Bad patents can slow down the process of conducting clinical trials, which can hinder innovation and make the process more expensive. The portal makes it easy to find scientific literature and published patents in the psychedelic space so that companies can file quality patents and spend fewer resources fighting patent cases.